国际口腔医学杂志 ›› 2018, Vol. 45 ›› Issue (2): 140-144.doi: 10.7518/gjkq.2018.02.004

• 口腔黏膜专栏 • 上一篇    下一篇

抗肿瘤靶向药物相关不良反应在口腔中的表现及处理对策

肖妍荻, 杨华梅, 但红霞   

  1. 口腔疾病研究国家重点实验室 国家口腔疾病临床医学研究中心
    四川大学华西口腔医院口腔黏膜病科 成都 610041
  • 收稿日期:2017-09-14 修回日期:2017-12-27 出版日期:2018-03-01 发布日期:2018-03-01
  • 通讯作者: 但红霞,副教授,博士,Email:hxdan@foxmail.com
  • 作者简介:肖妍荻,硕士,Email:272886584@qq.com
  • 基金资助:
    国家自然科学基金(81572663); 国家卫生与计划生育委员会公益性行业科研专项(201502018); 国家临床重点专科四川大学华西口腔医院口腔黏膜病科建设经费(2014)

Adverse reactions of targeted anticancer agents in oral cavity: manifestation and management

Xiao Yandi, Yang Huamei, Dan Hongxia   

  1. State Key Laboratory of Oral Diseases &National Clinical Research Center for Oral Diseases &Dept. of Oral Medicine, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, China
  • Received:2017-09-14 Revised:2017-12-27 Online:2018-03-01 Published:2018-03-01
  • Supported by:
    Specific Fund of National Health and Family Planning Commission of China (201502018) and National Key Clinical Program on Oral Mucosal Diseases in China (2014).

摘要: 近年来,抗肿瘤靶向药物被广泛应用于临床,其相关的不良反应也引起了学者的重视。口腔是靶向药物不良反应较常累及的部位,本文旨在对抗肿瘤靶向药物相关不良反应在口腔中的表现及处理进行综述,以期能提高临床医生对该现象的认识,提高患者的生存质量。

关键词: 靶向药物, 抗肿瘤治疗, 口腔, 药物不良反应, 处理对策

Abstract: Targeted therapy is widely used in cancer treatment. However, anticancer agents used in targeted therapy can induce various adverse reactions in oral cavity. This review aims to summarize the adverse reactions in oral cavity incurred during targeted therapy and the corresponding strategies for their management.

Key words: targeted agents, anticancer therapy, oral cavity, adverse drug reactions, managing strategies

中图分类号: 

  • R781.5
[1] Common terminology criteria for adverse events (CTCAE) version 4.0[S]. Bethesda: National Insti-tutes of Health, National Cancer Institute, 2009.
[2] Vigarios E, Epstein JB, Sibaud V.Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors[J]. Support Care Can-cer, 2017, 25(5):1713-1739.
[3] Yuan A, Woo SB.Adverse drug events in the oral cavity[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2015, 119(1):35-47.
[4] Shameem R, Lacouture M, Wu S.Incidence and risk of high-grade stomatitis with mTOR inhibitors in can-cer patients[J]. Cancer Invest, 2015, 33(3):70-77.
[5] Vargo CA, Berger MJ, Phillips G, et al.Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer[J]. Support Care Cancer, 2016, 24(7):2913-2918.
[6] Rugo HS, Hortobagyi GN, Yao J, et al.Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy[J]. Ann Oncol, 2016, 27(3):519-525.
[7] Kaplan B, Qazi Y, Wellen JR.Strategies for the ma-nagement of adverse events associated with mTOR inhibitors[J]. Transplant Rev (Orlando), 2014, 28(3): 126-133.
[8] Soria JC, Felip E, Cobo M, et al.Afatinib versus erlo-tinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2015, 16(8):897-907.
[9] Park K, Tan EH, O’Byrne K, et al. Afatinib versus ge-fitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J]. Lancet Oncol, 2016, 17(5):577-589.
[10] Burotto M, Manasanch EE, Wilkerson J, et al.Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials[J]. Oncologist, 2015, 20(4):400-410.
[11] Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma[J]. N Engl J Med, 2015, 373(19):1803-1813.
[12] Yamany T, Levender M, Silvers DN, et al.Erythema multiforme-like reaction with mucosal involvement following administration of idelalisib for relapse of chronic lymphocytic leukemia[J]. Leuk Lymphoma, 2015, 56(6):1872-1873.
[13] Edwards D, Boritz E, Cowen EW, et al.Erythema multiforme major following treatment with infliximab[J]. Oral Surg Oral Med Oral Pathol Oral Radiol, 2013, 115(2):e36-e40.
[14] Lowndes S, Darby A, Mead G, et al.Stevens-Johnson syndrome after treatment with rituximab[J]. Ann Oncol, 2002, 13(12):1948-1950.
[15] Peterson DE, O’Shaughnessy JA, Rugo HS, et al. Oral mucosal injury caused by mammalian target of rapa-mycin inhibitors: emerging perspectives on pathobio-logy and impact on clinical practice[J]. Cancer Med, 2016, 5(8):1897-1907.
[16] Kuten-Shorrer M, Hochberg EP, Woo SB.Lichenoid mucosal reaction to rituximab[J]. Oncologist, 2014, 19(10):e12-e13.
[17] Zhang JA, Yu JB, Li XH, et al.Oral and cutaneous lichenoid eruption with nail changes due to imatinib treatment in a chinese patient with chronic myeloid leukemia[J]. Ann Dermatol, 2015, 27(2):228-229.
[18] Luo JR, Xiang XJ, Xiong JP.Lichenoid drug eruption caused by imatinib mesylate in a Chinese patient with gastrointestinal stromal tumor[J]. Int J Clin Pharmacol Ther, 2016, 54(9):719-722.
[19] Bloom MD, Gibney JM, Heldermon CD.Pigmentation of the tongue with lapatinib treatment in a patient with advanced breast cancer: a case report[J]. Cancer Treat Commun, 2016, 7:1-3.
[20] Khoo TL, Catalano A, Supple S, et al.Hyperpigmen-tation of the hard palate associated with imatinib the-rapy for chronic myeloid leukemia with a genetic va-riation in the proto-oncogene c-KIT[J]. Leuk Lym-phoma, 2013, 54(1):186-188.
[21] Li CC, Malik SM, Blaeser BF, et al.Mucosal pigmenta-tion caused by imatinib: report of three cases[J]. Head Neck Pathol, 2012, 6(2):290-295.
[22] Ellis PM, Shepherd FA, Millward M, et al.Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial[J]. Lancet Oncol, 2014, 15(12):1379-1388.
[23] Rizvi NA, Mazières J, Planchard D, et al.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squa-mous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial[J]. Lancet Oncol, 2015, 16(3):257-265.
[24] Robert C, Schachter J, Long GV, et al.Pembrolizumab versus ipilimumab in advanced melanoma[J]. N Engl J Med, 2015, 372(26):2521-2532.
[25] Boer CC, Correa ME, Miranda EC, et al.Taste dis-orders and oral evaluation in patients undergoing allo-geneic hematopoietic SCT[J]. Bone Marrow Transplant, 2010, 45(4):705-711.
[26] Robert C, Long GV, Brady B, et al.Nivolumab in previously untreated melanoma without BRAF muta-tion[J]. N Engl J Med, 2015, 372(4):320-330.
[27] Tang N, Ratner D.Managing cutaneous side effects from targeted molecular inhibitors for melanoma and nonmelanoma skin cancer[J]. Dermatol Surg, 2016, 42(Suppl 1):S40-S48.
[28] Gavrilovic IT, Balagula Y, Rosen AC, et al.Charac-teristics of oral mucosal events related to bevacizu-mab treatment[J]. Oncologist, 2012, 17(2):274-278.
[29] Hubiche T, Valenza B, Chevreau C, et al.Geographic tongue induced by angiogenesis inhibitors[J]. Oncologist, 2013, 18(4):e16-e17.
[30] Rosen AC, Gavrilovic IT, Balagula Y, et al.In reply[J]. Oncologist, 2013, 18(4):e18.
[1] 和子慕, 李风兰. 数字化口腔定位支架在头颈部肿瘤放射治疗中的应用现状[J]. 国际口腔医学杂志, 2024, 51(1): 28-35.
[2] 傅豫, 何薇, 黄兰. 铁死亡在口腔疾病中的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 36-44.
[3] 李然,胡月,张宁,高瑞芳,王翔宇,葛学军. Toll样受体和白细胞介素-17单核苷酸多态性与口腔扁平苔藓易感性的相关性研究[J]. 国际口腔医学杂志, 2024, 51(1): 45-51.
[4] 周金阔,张晋弘,史晓晶,刘广顺,姜磊,刘倩峰. 长链非编码RNA小核仁RNA宿主基因22调控微小RNA-27b-3p对口腔鳞状细胞癌细胞增殖、侵袭和迁移的影响[J]. 国际口腔医学杂志, 2024, 51(1): 52-59.
[5] 李立恒,王蕊,王晓明,张智轶,张璇,安峰,王芹,张凡. 环状RNA hsa_circ_0085576调控微小RNA-498/B细胞特异性莫洛尼鼠白血病病毒整合位点1轴对口腔鳞状细胞癌细胞迁移和侵袭的影响[J]. 国际口腔医学杂志, 2024, 51(1): 60-67.
[6] 谭永臻,梁新华. 口腔局部麻醉药抗菌机制的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 74-81.
[7] 王楠楠,贺红,花放. 正畸相关釉质脱矿危险因素的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 91-98.
[8] 韩冲,何东宁,余飞燕,吴东潮. 口腔种植术后疼痛机制及治疗的研究进展[J]. 国际口腔医学杂志, 2024, 51(1): 99-106.
[9] 王素杰,谭芹,韦渊,王洁,范杰,岳二丽. 口腔扁平苔藓患者血清血管生成素-2水平与叉头翼状螺旋转录因子阳性调节性T细胞及疾病活动度的相关性分析[J]. 国际口腔医学杂志, 2023, 50(6): 674-678.
[10] 吴佳敏,夏斌,杨禾丰,许彪. 癌相关成纤维细胞在口腔鳞状细胞癌微环境中作用的研究进展[J]. 国际口腔医学杂志, 2023, 50(6): 711-717.
[11] 柳江龙, 买买提吐逊·吐尔地. 超声造影在口腔鳞状细胞癌颈部转移性淋巴结诊断中的研究进展[J]. 国际口腔医学杂志, 2023, 50(5): 514-520.
[12] 刘婷,武秀萍. 唐氏综合征的口腔-颅颌面表征及治疗进展[J]. 国际口腔医学杂志, 2023, 50(5): 618-622.
[13] 姜玥莹,何宇添,李婷,周蓉卉. 近红外荧光探针在口腔癌诊断中应用的研究进展[J]. 国际口腔医学杂志, 2023, 50(4): 407-413.
[14] 王铝亚,张竞心,林洁. 口腔术后聚维酮碘与氯己定控制感染效果的系统评价分析[J]. 国际口腔医学杂志, 2023, 50(4): 438-444.
[15] 范琳,孙江. 微针在口腔医学中的应用[J]. 国际口腔医学杂志, 2023, 50(4): 472-478.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] 王昆润. 二甲亚砜和双氯芬酸并用治疗根尖周炎[J]. 国际口腔医学杂志, 1999, 26(06): .
[2] 汤庆奋,王学侠. 17β-雌二醇对人类阴道和口腔颊粘膜的渗透性[J]. 国际口腔医学杂志, 1999, 26(06): .
[3] 潘劲松. 颈总动脉指压和颈内动脉球囊阻断试验在大脑血液动力学中的不同影响[J]. 国际口腔医学杂志, 1999, 26(05): .
[4] 王昆润. 后牙冠根斜形牙折的治疗[J]. 国际口腔医学杂志, 1999, 26(05): .
[5] 杨锦波. 嵌合体防龋疫苗的研究进展[J]. 国际口腔医学杂志, 1999, 26(05): .
[6] 王昆润. 下颔骨成形术用网状钛板固定植骨块[J]. 国际口腔医学杂志, 1999, 26(04): .
[7] 汪月月,郭莉莉. 口腔机能与老化—痴呆危险因素流行病学研究[J]. 国际口腔医学杂志, 1999, 26(04): .
[8] 丁刚. 应用硬组织代用品种植体行丰颏术[J]. 国际口腔医学杂志, 1999, 26(04): .
[9] 田磊. 局部应用脂多糖后结合上皮反应性增生的变化[J]. 国际口腔医学杂志, 1999, 26(04): .
[10] 戴青. 口腔念珠菌病的新分类[J]. 国际口腔医学杂志, 1999, 26(04): .